HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 321 filers reported holding HALOZYME THERAPEUTICS INC in Q4 2021. The put-call ratio across all filers is 0.39 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $525,900 | +66.8% | 13,767 | +57.5% | 0.02% | +45.5% |
| Q2 2023 | $315,216 | +134034.5% | 8,739 | +42.3% | 0.01% | +57.1% |
| Q1 2023 | $235 | -15.8% | 6,142 | +25.3% | 0.01% | -41.7% |
| Q4 2022 | $279 | -99.9% | 4,903 | -61.8% | 0.01% | +50.0% |
| Q3 2022 | $507,000 | -62.2% | 12,829 | -57.9% | 0.01% | -73.3% |
| Q2 2022 | $1,342,000 | +304.2% | 30,489 | +265.4% | 0.03% | +900.0% |
| Q1 2022 | $332,000 | -43.9% | 8,344 | -43.3% | 0.00% | -70.0% |
| Q4 2021 | $592,000 | -4.1% | 14,714 | -3.0% | 0.01% | -37.5% |
| Q3 2021 | $617,000 | -54.3% | 15,165 | -49.0% | 0.02% | -54.3% |
| Q2 2021 | $1,350,000 | -11.5% | 29,723 | -18.8% | 0.04% | +34.6% |
| Q1 2021 | $1,526,000 | +225.4% | 36,605 | +233.0% | 0.03% | +85.7% |
| Q4 2020 | $469,000 | +393.7% | 10,991 | +203.9% | 0.01% | +1300.0% |
| Q3 2020 | $95,000 | -82.7% | 3,617 | -82.3% | 0.00% | -95.7% |
| Q2 2020 | $550,000 | +38.9% | 20,492 | -8.3% | 0.02% | -30.3% |
| Q4 2019 | $396,000 | +39500.0% | 22,347 | +33253.7% | 0.03% | – |
| Q3 2019 | $1,000 | -66.7% | 67 | -66.5% | 0.00% | – |
| Q2 2019 | $3,000 | -89.7% | 200 | -89.0% | 0.00% | -100.0% |
| Q1 2019 | $29,000 | +383.3% | 1,818 | +366.2% | 0.00% | – |
| Q4 2018 | $6,000 | -73.9% | 390 | -71.5% | 0.00% | -100.0% |
| Q2 2018 | $23,000 | -90.5% | 1,369 | -90.2% | 0.00% | -95.0% |
| Q3 2017 | $243,000 | +200.0% | 13,989 | +69.6% | 0.02% | +122.2% |
| Q4 2016 | $81,000 | +131.4% | 8,247 | +183.8% | 0.01% | +200.0% |
| Q3 2016 | $35,000 | +400.0% | 2,906 | +275.0% | 0.00% | +200.0% |
| Q2 2016 | $7,000 | -50.0% | 775 | -48.6% | 0.00% | -50.0% |
| Q1 2016 | $14,000 | -89.3% | 1,508 | -84.6% | 0.00% | -84.6% |
| Q3 2015 | $131,000 | +991.7% | 9,779 | +1113.3% | 0.01% | +1200.0% |
| Q1 2015 | $12,000 | – | 806 | – | 0.00% | – |
| Q3 2014 | $0 | -100.0% | 0 | -100.0% | 0.00% | – |
| Q2 2014 | $1,000 | -99.7% | 70 | -99.8% | 0.00% | -100.0% |
| Q1 2014 | $383,000 | +5371.4% | 30,136 | +6479.9% | 0.05% | +4800.0% |
| Q4 2013 | $7,000 | -83.7% | 458 | -88.4% | 0.00% | -80.0% |
| Q3 2013 | $43,000 | – | 3,933 | +32675.0% | 0.01% | – |
| Q2 2013 | $0 | – | 12 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Third Security, LLC | 19,829,337 | $266,308,000 | 10.60% |
| BB BIOTECH AG | 6,929,832 | $93,068,000 | 2.95% |
| SECTORAL ASSET MANAGEMENT INC | 2,671,051 | $35,872,000 | 1.64% |
| Sterling Global Strategies LLC | 22,000 | $295,000 | 1.63% |
| Lombard Odier Asset Management (USA) Corp | 1,061,547 | $14,257,000 | 1.24% |
| PYRRHO CAPITAL MANAGEMENT, LP | 90,000 | $1,209,000 | 1.04% |
| IRIDIAN ASSET MANAGEMENT LLC/CT | 8,184,003 | $109,911,000 | 0.93% |
| Bellevue Asset Management AG | 246,000 | $3,304,000 | 0.54% |
| Convergence Investment Partners, LLC | 251,748 | $3,381,000 | 0.39% |
| Rhenman & Partners Asset Management AB | 172,000 | $2,310,000 | 0.37% |